Key Highlights

  • Johnson & Johnson (NYSE:JNJ) reported third quarter 2026 net Earnings of USD 210 million, down 95.9% from USD 5,152 million, with reported Diluted Earnings per Share of USD 0.09 against USD 2.12 a year earlier.
  • The release attributes the fall to a one-time special charge for the proposed talc litigation resolution, along with the Firefly Bio Acquisition and a collaboration with Sail Biomedicines. It does not give the size of the talc charge.
  • Adjusted net earnings were USD 6,339 million, down 6.8%, and adjusted earnings per share were USD 2.59, down 7.5%, on reported sales of USD 25.4 billion, up 5.9% from USD 23.99 billion.
  • Published market data show JNJ at USD 270.56, down 0.97% in the latest session, with trailing Net Income of USD 26.80 billion and a price to earnings ratio of 41.04. These screener figures are unverified.

A Reported Profit Almost Wiped Out

Johnson & Johnson reported third quarter 2026 results with sales of USD 25.4 billion, up 5.9%. Reported net earnings fell to USD 210 million from USD 5,152 million, and earnings per share to USD 0.09 from USD 2.12. The release points to a one-time special charge for the proposed talc litigation resolution, plus charges tied to acquiring Firefly Bio and to a strategic collaboration with Sail Biomedicines. Johnson & Johnson (NYSE:JNJ) did not break out the amount of the talc charge in the release we checked, so its size cannot be stated.

Reported Versus Adjusted Profit

Companies in the healthcare sector often publish adjusted earnings that exclude acquisition costs and litigation items, which is why two very different numbers describe the same quarter. Adjusted net earnings of USD 6,339 million were down 6.8%, a modest decline. Adjusted earnings per share of USD 2.59 fell 7.5% and also reflect the two deals. The trailing net income of USD 26.80 billion on published market data is an unverified screener figure, but its trailing earnings per share of USD 6.59 and a negative growth rate of 36.38% on the same data show the charge already working through. A price to earnings ratio of 41.04 on that depressed base should therefore be read with caution.

Risks and What to Watch

Litigation resolution carries uncertainty over the final cost, timing and court approval, and the release gave no size for the charge. The company raised 2026 guidance, with estimated reported sales of USD 101.0 billion to USD 101.4 billion and adjusted diluted earnings per share of USD 11.05 to USD 11.15, a midpoint of USD 11.10 that is up USD 0.06. Those are company estimates, not forecasts of ours. Acquisition integration and pipeline spending are further risks. On screener data JNJ fell 0.97% in the latest session, and the next Quarterly Report is normally due in mid January, a date not confirmed. Medical device and pharmaceutical segment trends, Patent expiries on older drugs and any court decision on the talc proposal could each change the earnings path, so the reported figure alone is a poor guide to the following quarters.

Where Things Stand

Johnson & Johnson's net earnings fell to USD 210 million because of a one-time talc litigation charge and deal related costs, while adjusted earnings per share of USD 2.59 fell a more modest 7.5%. The company raised 2026 guidance, which suggests operations are on track. Johnson & Johnson (NYSE:JNJ) still ranks among the largest earners on trailing data, but the size of the talc charge and the final litigation outcome are the open questions.